Fmr LLC Acquires 824,750 Shares of argenx SE (NASDAQ:ARGX)

Fmr LLC boosted its position in shares of argenx SE (NASDAQ:ARGX) by 17.2% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 5,618,222 shares of the company’s stock after buying an additional 824,750 shares during the quarter. Fmr LLC owned approximately 9.25% of argenx worth $3,455,207,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Clearbridge Investments LLC grew its holdings in argenx by 6.8% during the fourth quarter. Clearbridge Investments LLC now owns 629,828 shares of the company’s stock valued at $387,344,000 after purchasing an additional 40,330 shares during the period. Wellington Management Group LLP raised its holdings in argenx by 13.0% during the third quarter. Wellington Management Group LLP now owns 482,346 shares of the company’s stock worth $261,470,000 after acquiring an additional 55,617 shares in the last quarter. Jennison Associates LLC boosted its holdings in shares of argenx by 27.0% in the 4th quarter. Jennison Associates LLC now owns 302,149 shares of the company’s stock valued at $185,821,000 after buying an additional 64,183 shares during the last quarter. Lord Abbett & CO. LLC bought a new position in shares of argenx in the 3rd quarter valued at about $88,339,000. Finally, Allspring Global Investments Holdings LLC increased its position in argenx by 38,152.3% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 144,211 shares of the company’s stock worth $89,391,000 after buying an additional 143,834 shares during the last quarter. 60.32% of the stock is owned by institutional investors.

argenx Price Performance

Shares of NASDAQ:ARGX opened at $555.11 on Friday. argenx SE has a 1 year low of $352.77 and a 1 year high of $678.21. The firm has a market capitalization of $33.73 billion, a P/E ratio of -630.81 and a beta of 0.60. The business’s 50-day moving average is $621.43 and its 200 day moving average is $603.18.

argenx (NASDAQ:ARGX) last released its quarterly earnings data on Thursday, February 27th. The company reported $1.58 EPS for the quarter, beating the consensus estimate of $0.98 by $0.60. The business had revenue of $761.22 million for the quarter, compared to the consensus estimate of $678.52 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. On average, analysts expect that argenx SE will post 3.13 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on ARGX shares. HC Wainwright raised their price target on shares of argenx from $717.00 to $720.00 and gave the stock a “buy” rating in a research report on Friday, February 28th. Truist Financial restated a “buy” rating and issued a $700.00 price target (up from $660.00) on shares of argenx in a research note on Tuesday, January 14th. Robert W. Baird upped their target price on argenx from $650.00 to $680.00 and gave the stock a “neutral” rating in a report on Tuesday, March 4th. William Blair reaffirmed an “outperform” rating on shares of argenx in a research report on Friday, February 28th. Finally, JMP Securities boosted their price target on shares of argenx from $606.00 to $696.00 and gave the stock a “market outperform” rating in a research report on Tuesday, January 14th. Three investment analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $687.00.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.